Review



as1842856  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    MedChemExpress as1842856
    As1842856, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 126 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/as1842856/product/MedChemExpress
    Average 97 stars, based on 126 article reviews
    as1842856 - by Bioz Stars, 2026-02
    97/100 stars

    Images



    Similar Products

    97
    MedChemExpress as1842856
    As1842856, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/as1842856/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    as1842856 - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    97
    MedChemExpress aav acadl as1842856 group
    Aav Acadl As1842856 Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aav acadl as1842856 group/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    aav acadl as1842856 group - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    97
    MedChemExpress as1842856 as18
    As1842856 As18, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/as1842856 as18/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    as1842856 as18 - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    97
    MedChemExpress as1842856 celltiter 96 aqueous one solution cell proliferation assay promega
    As1842856 Celltiter 96 Aqueous One Solution Cell Proliferation Assay Promega, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/as1842856 celltiter 96 aqueous one solution cell proliferation assay promega/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    as1842856 celltiter 96 aqueous one solution cell proliferation assay promega - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    97
    MedChemExpress foxo inhibitor
    EGFR TKI dephosphorylates FoxO3a to induce ALPP expression (A and B) Immunoblots for ALPP, pAKT-S473, total AKT, pERK-T202/Y204, total ERK, pSTAT1-Y701, pSTAT1-S727, total STAT1, and β-actin in LUAD cancer cells H2291 and H1650 following 24- and 48-h treatment with or without EGF (10 or 20 ng/mL) or gefitinib (0.5 or 1 μM). Representative blot of three replicates. (C) Immunoblots for ALPP and β-actin in HCC827 and PC9 cell treated with <t>PI3K</t> <t>inhibitor</t> NVP-BKM120 (100 nM), MEK inhibitor AZD8330 (100 nM), and ERK inhibitor SCH772984 (100 nM) for 48 h. Representative blot of three replicates. (D and E) Immunoblots for ALPP and β-actin in HCC827 and PC9 cell treated with <t>FOXO</t> inhibitor AS1842856 with vehicle or gefitinib for 48 h. Representative blot of three replicates. (F) Immunoblots for ALPP and FoxO3a in FoxO3a-overexpressing HCC827 and H1650 LUAD cells treated with vehicle or gefitinib (30 nM) for 48 h. Representative blot of three replicates. (G) Immunoblots for ALPP, FoxO3a, and phosphorylated FoxO3a (Ser294 and Ser425) in HCC827 and H1650 cells treated with 30 nM gefitinib for 6 h. Representative blot of three replicates. (H) Immunoblots for FoxO3a in the cytosol and nucleus compartment from gefitinib-treated HC827 and H1650 cell lines. Representative blot of three replicates. (I) Immunoblots for ALPP, EGFR, pEGFR (Tyr1068), FoxO3a, pFoxO3a (Ser294), and β-Actin in HCC827 and PC9 cells treated with gefitinib (30 nM) or osimertinib (30 nM). Representative blot of three replicates. (J) ChIP-qPCR assay for the promoter region of ALPP gene in HCC827 and H1650 LUAD cells treated with either vehicle or gefitinib (1 μM) for 6 h ( n = 3 biological replicates). Data are presented as mean ± SD. Statistical significance was determined using Dunnett’s multiple comparisons test, and adjusted p values are reported.
    Foxo Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/foxo inhibitor/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    foxo inhibitor - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    97
    MedChemExpress foxo 1 inhibitor
    EGFR TKI dephosphorylates FoxO3a to induce ALPP expression (A and B) Immunoblots for ALPP, pAKT-S473, total AKT, pERK-T202/Y204, total ERK, pSTAT1-Y701, pSTAT1-S727, total STAT1, and β-actin in LUAD cancer cells H2291 and H1650 following 24- and 48-h treatment with or without EGF (10 or 20 ng/mL) or gefitinib (0.5 or 1 μM). Representative blot of three replicates. (C) Immunoblots for ALPP and β-actin in HCC827 and PC9 cell treated with <t>PI3K</t> <t>inhibitor</t> NVP-BKM120 (100 nM), MEK inhibitor AZD8330 (100 nM), and ERK inhibitor SCH772984 (100 nM) for 48 h. Representative blot of three replicates. (D and E) Immunoblots for ALPP and β-actin in HCC827 and PC9 cell treated with <t>FOXO</t> inhibitor AS1842856 with vehicle or gefitinib for 48 h. Representative blot of three replicates. (F) Immunoblots for ALPP and FoxO3a in FoxO3a-overexpressing HCC827 and H1650 LUAD cells treated with vehicle or gefitinib (30 nM) for 48 h. Representative blot of three replicates. (G) Immunoblots for ALPP, FoxO3a, and phosphorylated FoxO3a (Ser294 and Ser425) in HCC827 and H1650 cells treated with 30 nM gefitinib for 6 h. Representative blot of three replicates. (H) Immunoblots for FoxO3a in the cytosol and nucleus compartment from gefitinib-treated HC827 and H1650 cell lines. Representative blot of three replicates. (I) Immunoblots for ALPP, EGFR, pEGFR (Tyr1068), FoxO3a, pFoxO3a (Ser294), and β-Actin in HCC827 and PC9 cells treated with gefitinib (30 nM) or osimertinib (30 nM). Representative blot of three replicates. (J) ChIP-qPCR assay for the promoter region of ALPP gene in HCC827 and H1650 LUAD cells treated with either vehicle or gefitinib (1 μM) for 6 h ( n = 3 biological replicates). Data are presented as mean ± SD. Statistical significance was determined using Dunnett’s multiple comparisons test, and adjusted p values are reported.
    Foxo 1 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/foxo 1 inhibitor/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    foxo 1 inhibitor - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    Image Search Results


    EGFR TKI dephosphorylates FoxO3a to induce ALPP expression (A and B) Immunoblots for ALPP, pAKT-S473, total AKT, pERK-T202/Y204, total ERK, pSTAT1-Y701, pSTAT1-S727, total STAT1, and β-actin in LUAD cancer cells H2291 and H1650 following 24- and 48-h treatment with or without EGF (10 or 20 ng/mL) or gefitinib (0.5 or 1 μM). Representative blot of three replicates. (C) Immunoblots for ALPP and β-actin in HCC827 and PC9 cell treated with PI3K inhibitor NVP-BKM120 (100 nM), MEK inhibitor AZD8330 (100 nM), and ERK inhibitor SCH772984 (100 nM) for 48 h. Representative blot of three replicates. (D and E) Immunoblots for ALPP and β-actin in HCC827 and PC9 cell treated with FOXO inhibitor AS1842856 with vehicle or gefitinib for 48 h. Representative blot of three replicates. (F) Immunoblots for ALPP and FoxO3a in FoxO3a-overexpressing HCC827 and H1650 LUAD cells treated with vehicle or gefitinib (30 nM) for 48 h. Representative blot of three replicates. (G) Immunoblots for ALPP, FoxO3a, and phosphorylated FoxO3a (Ser294 and Ser425) in HCC827 and H1650 cells treated with 30 nM gefitinib for 6 h. Representative blot of three replicates. (H) Immunoblots for FoxO3a in the cytosol and nucleus compartment from gefitinib-treated HC827 and H1650 cell lines. Representative blot of three replicates. (I) Immunoblots for ALPP, EGFR, pEGFR (Tyr1068), FoxO3a, pFoxO3a (Ser294), and β-Actin in HCC827 and PC9 cells treated with gefitinib (30 nM) or osimertinib (30 nM). Representative blot of three replicates. (J) ChIP-qPCR assay for the promoter region of ALPP gene in HCC827 and H1650 LUAD cells treated with either vehicle or gefitinib (1 μM) for 6 h ( n = 3 biological replicates). Data are presented as mean ± SD. Statistical significance was determined using Dunnett’s multiple comparisons test, and adjusted p values are reported.

    Journal: Cell Reports Medicine

    Article Title: Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy

    doi: 10.1016/j.xcrm.2025.102513

    Figure Lengend Snippet: EGFR TKI dephosphorylates FoxO3a to induce ALPP expression (A and B) Immunoblots for ALPP, pAKT-S473, total AKT, pERK-T202/Y204, total ERK, pSTAT1-Y701, pSTAT1-S727, total STAT1, and β-actin in LUAD cancer cells H2291 and H1650 following 24- and 48-h treatment with or without EGF (10 or 20 ng/mL) or gefitinib (0.5 or 1 μM). Representative blot of three replicates. (C) Immunoblots for ALPP and β-actin in HCC827 and PC9 cell treated with PI3K inhibitor NVP-BKM120 (100 nM), MEK inhibitor AZD8330 (100 nM), and ERK inhibitor SCH772984 (100 nM) for 48 h. Representative blot of three replicates. (D and E) Immunoblots for ALPP and β-actin in HCC827 and PC9 cell treated with FOXO inhibitor AS1842856 with vehicle or gefitinib for 48 h. Representative blot of three replicates. (F) Immunoblots for ALPP and FoxO3a in FoxO3a-overexpressing HCC827 and H1650 LUAD cells treated with vehicle or gefitinib (30 nM) for 48 h. Representative blot of three replicates. (G) Immunoblots for ALPP, FoxO3a, and phosphorylated FoxO3a (Ser294 and Ser425) in HCC827 and H1650 cells treated with 30 nM gefitinib for 6 h. Representative blot of three replicates. (H) Immunoblots for FoxO3a in the cytosol and nucleus compartment from gefitinib-treated HC827 and H1650 cell lines. Representative blot of three replicates. (I) Immunoblots for ALPP, EGFR, pEGFR (Tyr1068), FoxO3a, pFoxO3a (Ser294), and β-Actin in HCC827 and PC9 cells treated with gefitinib (30 nM) or osimertinib (30 nM). Representative blot of three replicates. (J) ChIP-qPCR assay for the promoter region of ALPP gene in HCC827 and H1650 LUAD cells treated with either vehicle or gefitinib (1 μM) for 6 h ( n = 3 biological replicates). Data are presented as mean ± SD. Statistical significance was determined using Dunnett’s multiple comparisons test, and adjusted p values are reported.

    Article Snippet: FoxO inhibitor , MedChemExpress , Cat# AS1842856.

    Techniques: Expressing, Western Blot, ChIP-qPCR